About my Novartis blogs
The Short Version
I was the CIO of the Novartis Institutes for BioMedical Research (NIBR), the Research business unit of Novartis, from the end of 2006 into early 2018. It was an amazing, crazy, challenging impactful journey, one for which I will always be grateful to Novartis for enabling.
While I was there, I blogged internally, making posts available inside the Novartis network.
Since leaving, I’ve been asked occasionally if I still have “that one blog”. And sometimes I want to point someone to one of the advice notes, or one of the sillier rants.
So, I have re-posted a very few of those blogs here, on my personal blog (you can find them all tagged with “nibr-blog” and on that nibr-blog tag page).
To be clear:
- None of these blogs have any sensitive Novartis information.
- These blogs are not particularly representative of what was going on inside NIBR at the time. This is not a history or archive or anything like that.
- This is just the small subset of my writing that is useful or amusing to share externally, more than 10 years after I wrote these.
In other words - these are a very narrow glimpse into the mind of a CIO focused on Discovery in Big Pharma in the 2010s, going through complex organizational changees, digital transformation, and the challenges of raising a family in today’s society while trying not to break too many bones on bikes.
A bit more background on my NIBR blog
I initially started blogging because I needed to communicate with my organization about what I was learning, what I was planning, and where we were going. I also used email, but email is transient, ephemeral, and yet another thing in the Inbox. I needed to share information in a way that it could be referenced over time, in a way that it could be read when someone was in a reflective mode, and in a way that gave me the room to explore topics in long form. So I started blogging on some web platform we had at the time, just so I had a place that I could post and share links.
I think I was the first executive in Novartis to blog. Several others did too, including some of the CEOs, with the support of their marketing teams, but blogging never became a widely-used communication tool.
Writing is my most effective tool for learning what I think. The blog helped me learn so much… what I was thinking, what was important to me, what was important to my organization, what they heard when I communicated.
I wrote mostly about organizational issues and topics of the moment. Sometimes I posted about silly things or my musings about some new technology shift. Sometimes I took what was going on at Novartis and added commentary or explanation. Everything I posted was my own writing, although I quickly learned to review drafts with people who knew what they were talking about…
Over time, the blog became one of the things I was known for across the company. I would be stopped in cafeterias in Basel by scientists I’d never met before, who would ask me about my latest cycling trip, or would have questions and suggestions about IT projects underway. My blogs on how to handle performance management were circulated around the entire company. I wrote about the challenges of working across timezones, and heard back from seemingly half of our employees in Asia. Some of my blogs were commented on for years. Some were PR disasters, including one notable one that required an apologetic follow up. People would join my organization, read all the blogs I’d written over the years, and then get in touch with me with questions about something from three years before.
It was pretty amazing, really. When I started, I had no idea it would be that useful or impactful.
My blogging was never on a regular schedule, despite my attempts to get to that point. I wrote when I needed to, when it felt right. Some years, I was fairly prolific. Other years, I would go months without an update.
Over my 12 years there, I wrote over 200 blog entries.
Years after leaving Novartis, I am occasionally asked by former colleagues about something I wrote there, wondering if I still have the blogs around.
When I left, I asked about taking copies of the blogs specifically, and Novartis was ok with that. There was never anything in any of them that is business- or IP-sensitive. (I never posted about, for example, targets or deep business competition.) However, the vast majority of what I wrote was about Novartis internal activities and was very specific to what was going on at the time, and is really just not interesting or appropriate to share outside Novartis these years later.
So, for those few things that I’ve been asked about or seem relevant, I’ve gone back through the archives and reposted them here.
The Story Arc
As context for these blog entries, here’s a bit more of what was going on during some of these years.
- 2007 - We got started. Organizational basics for NIBR’s global scientific IT group.
- 2008 - The org defined roadmaps and projects aiming to signifcantly improve the state of Scientific IT in NIBR.
- 2009 - New applications, infrastructure upgrades, and internal audits, all going well. We had positive reviews of our science programs.
- 2010 - We tackled bigger IT challenges like cross-company collaboration, the core data foundation for NIBR and started to focus on management skills. I broke my collarbone in a bike wreck.
- 2011 - We helped modernize Novartis by moving to Outlook, made significant scientific improvements, explored eHealth. We received major accolades from NIBR leadership on the impact that NIBR IT had on NIBR.
- 2012 - Shifted from a department focus to a cross-NIBR enterprise application focus for more strategic impact, and began to expand into data science. And I broke my collarbone again in another bike wreck, becoming the source of many jokes inside Novartis.
- 2013 - Budget constraints began to limit project impact as we focused more on cross-NIBR data initiatives.
- 2014 - Novartis centralized all other IT units, during which my responsibilities expanded to include Development IT. My Research team spent most of their time on prioritization and cost-reduction, while storage and computing needs grew exponentially with imaging and sequencing data explosion.
- 2015 - I helped launch a modernization of Development IT systems, then returned to NIBR full-time to focus on the triple challenges of increasing demand, decreasing funds, and organizational gridlock.
- 2016 - We started to focus on machine learning as a potential for changing Discovery, while continuing to scale back project efforts, and getting serious about a move to the cloud to address technical debt and increase flexibility. I developed a debilitating spine problem and could barely walk by the end of the year.
- 2017 - Novartis got serious about Digital. I launched a reorg to address organizational friction and budget realities. I also had back surgery, then slowly recovered over the course of the year.
- 2018 - In spring, I resigned to focus on my health recovery. I walked away having been through very high highs and some pretty low lows, knowing that my team had been extremely impactful for NIBR over the years, but was still facing challenges.
That’s a brief summary, more than enough for the context in the blog.
A few years after leaving NIBR, I pulled together a talk that looks back at the challenges my organization faced, where we made progress, and where I would do things differently. If you’re interested in that talk, let me know.